Actos®

The FDA warning was based on a study that shows that an increased risk of bladder cancer was found among patients with the longest exposure to pioglitazone, and in those exposed to the highest cumulative dose of pioglitazone.

France and Germany move to restrict use

The warning notes that France and Germany both moved to restrict the use of pioglitazone after a French study linked an increased risk of bladder cancer to long-term use.

Actos® is widely prescribed for diabetes control

Pioglitazone is also a key ingredient in the drugs Actoplus Met, Actoplus Met XR and Duetact. In the first ten months of 2010, more than 2.3 million patients were prescribed a pioglitazone-containing product.

Protect your rights. Get compensated for your injuries.

If you or a loved one developed bladder cancer or died after using Actos®, you may be entitled to compensation. Complete the Quick Intake form at the top of this page or call our legal intake center at 1 (800) 438-6453 to receive your FREE case evaluation.

[1] “FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer”